Case Report: A Bilateral Synchronous Primary Non-Small Cell Lung Cancer Patient With Two Different EGFR Mutations

IF 1.9 Q4 ONCOLOGY
Cancer reports Pub Date : 2025-08-25 DOI:10.1002/cnr2.70319
Thanh-Dung Quach, Kien Hung Do, Dinh Tung Nguyen, Hyeon-Gyu Yi, Thi-Phuong Vu, Tran Thanh Tin, Nghi Le Vinh, Son Hai Vu
{"title":"Case Report: A Bilateral Synchronous Primary Non-Small Cell Lung Cancer Patient With Two Different EGFR Mutations","authors":"Thanh-Dung Quach,&nbsp;Kien Hung Do,&nbsp;Dinh Tung Nguyen,&nbsp;Hyeon-Gyu Yi,&nbsp;Thi-Phuong Vu,&nbsp;Tran Thanh Tin,&nbsp;Nghi Le Vinh,&nbsp;Son Hai Vu","doi":"10.1002/cnr2.70319","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Non-small cell lung cancer (NSCLC) represents the majority of lung cancer cases, with epidermal growth factor receptor (EGFR) mutations playing a crucial role in disease prognosis and treatment. Around half of Asian patients with NSCLC, particularly non-smoking women, have EGFR mutations. These patients with NSCLC typically exhibit a single EGFR mutation in exon 18, 19, 20, or 21. It is extremely rare for patients with bilateral primary NSCLC to harbor two different EGFR mutations.</p>\n </section>\n \n <section>\n \n <h3> Case</h3>\n \n <p>We report a case of 70-year-old non-smoking Vietnamese female patient diagnosed with synchronous bilateral primary NSCLC, each harboring different EGFR mutations—G719C in exon 18 in the right lung and an exon 19 deletion in the left lung. The patient underwent surgical resection of the left lung lesion, followed by targeted therapy with afatinib for the right lung lesion, which resulted in tumor reduction and disease stability for 1 year before disease progression.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our study underscores the complexity of diagnosing and managing synchronous bilateral NSCLC with distinct genetic profiles. This report also highlights the importance of comprehensive molecular profiling to select an optimal treatment strategy to improve patient outcomes.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70319","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70319","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Non-small cell lung cancer (NSCLC) represents the majority of lung cancer cases, with epidermal growth factor receptor (EGFR) mutations playing a crucial role in disease prognosis and treatment. Around half of Asian patients with NSCLC, particularly non-smoking women, have EGFR mutations. These patients with NSCLC typically exhibit a single EGFR mutation in exon 18, 19, 20, or 21. It is extremely rare for patients with bilateral primary NSCLC to harbor two different EGFR mutations.

Case

We report a case of 70-year-old non-smoking Vietnamese female patient diagnosed with synchronous bilateral primary NSCLC, each harboring different EGFR mutations—G719C in exon 18 in the right lung and an exon 19 deletion in the left lung. The patient underwent surgical resection of the left lung lesion, followed by targeted therapy with afatinib for the right lung lesion, which resulted in tumor reduction and disease stability for 1 year before disease progression.

Conclusion

Our study underscores the complexity of diagnosing and managing synchronous bilateral NSCLC with distinct genetic profiles. This report also highlights the importance of comprehensive molecular profiling to select an optimal treatment strategy to improve patient outcomes.

Abstract Image

病例报告:双侧同步原发性非小细胞肺癌患者两种不同的EGFR突变
背景非小细胞肺癌(NSCLC)占肺癌病例的大多数,表皮生长因子受体(EGFR)突变在疾病预后和治疗中起着至关重要的作用。大约一半的亚洲非小细胞肺癌患者,尤其是不吸烟的女性,有EGFR突变。这些非小细胞肺癌患者通常在18、19、20或21外显子表现出单个EGFR突变。双侧原发性NSCLC患者携带两种不同的EGFR突变是极为罕见的。我们报告了一例70岁的越南非吸烟女性患者,诊断为同步双侧原发性NSCLC,每个患者都有不同的EGFR突变-右肺18外显子g719c和左肺19外显子缺失。患者行左肺病变手术切除,右肺病变行阿法替尼靶向治疗,肿瘤缩小,病情稳定1年,病情未进展。结论本研究强调了诊断和治疗具有不同遗传谱的同步双侧非小细胞肺癌的复杂性。该报告还强调了综合分子谱分析对选择最佳治疗策略以改善患者预后的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer reports
Cancer reports Medicine-Oncology
CiteScore
2.70
自引率
5.90%
发文量
160
审稿时长
17 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信